Carissa Beaudreau, OD
Optometrist · Oklahoma City, OKNPI 1154933638
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,610 of the $6,490 with a category attached, or 71.0%. 18 manufacturers reported payments, led by Glaukos Corporation at 48.2% of the total. 2025 is the largest year on record at $3,760, more than ten times the $197 reported in 2021. Among optometrist clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $38.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$3K
- Alcon$622
- AbbVie$604
- Bausch & Lomb Americas Inc.$485
- Sight Sciences, Inc.$285
- Rxsight Inc$263
- plus $1K from 12 others
Across 8 payments — averaging $257.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$2K
What the payments were for
- Travel & lodging$1,87929%
- Food & beverage$4,61071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 23 | $3,129 |
| Alcon | 41 | $622 |
| AbbVie | 35 | $604 |
| Bausch & Lomb Americas Inc. | 16 | $485 |
| Sight Sciences, Inc. | 6 | $285 |
| Rxsight Inc | 3 | $263 |
| Harrow Eye, LLC | 10 | $242 |
| Tarsus Pharmaceuticals, Inc. | 7 | $220 |
| Johnson & Johnson Vision Care, Inc. | 5 | $171 |
| Novartis | 9 | $149 |
| Coopervision Inc. | 3 | $110 |
| Dompe US, Inc. | 2 | $59 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $40 |
| Tearlab Corp | 2 | $35 |
| Sun Pharmaceutical Industries Inc. | 2 | $33 |
| Apellis Pharmaceuticals, Inc. | 1 | $17 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $14 |
| Rayner Intraocular Lenses Limited | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDoseTR$2,585
- iStent Infinite$2,585
- iStent Trabecular Micro-Bypass Stent System$144
- iStent infinite Trabecular Micro-Bypass System Model iS3$144
- iStent Inject Trabecular Micro-Bypass System$144
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$138
- TEARCARE SYSTEM$138
- XDEMVY$124
- MIEBO$124
- XIIDRA$124
- Rocklatan$117
- Rhopressa$117
- SIMBRINZA$117
- VUITY$111
- RXSIGHT CONTACT LENS$107
- RXSIGHT INJECTOR CARTRIDGE$107
- RXSIGHT INJECTOR HANDPIECE$107
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$107
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$107
How this compares
$6,490 in reported general payments places this provider in the 90th percentile of 714 optometrist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 69 | $66,489 |
| XiidraLifitegrast | 14 | $20,263 |
| RocklatanNetarsudil Mesylat/Latanoprost | 28 | $10,073 |
| MieboPerfluorohexyloctane/Pf | 12 | $8,832 |
| LumiganBimatoprost | 19 | $8,630 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $8,138 |
| RhopressaNetarsudil Mesylate | 21 | $6,722 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 31 | $6,475 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 27 | $5,512 |
| Latanoprost | 201 | $2,142 |
| Brimonidine Tartrate | 59 | $1,952 |
| Prednisolone Acetate | 63 | $1,760 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 82 | $1,346 |
| Timolol Maleate | 84 | $1,342 |
| Dorzolamide Hcl | 39 | $857 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $604 | $83,257104 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $485 | $29,09526 claims |
| AlconSimbrinza | $622 | $5,51227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 714 optometrist providers in Oklahoma.
Other optometrist in Oklahoma City
- Joseph PhillipsOklahoma City$52K
- Scott ForesterOklahoma City$17K
- Trent PittOklahoma City$15K
- Kong ChangOklahoma City$7K
- Bradley DanielOklahoma City$7K
- Kenneth GuthrieOklahoma City$7K
- Myranda PartinOklahoma City$7K
- Trevor ConklinOklahoma City$7K
- Colby RicksOklahoma City$6K
- Rachel CaywoodOklahoma City$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.